Interview with Dr. Ian T. Young, Chair, Medical Delta
14.02.2011
Related Interviews
Interview: Paul Korte – General Manager, Janssen Netherlands
Paul Korte, General Manager for Janssen in the Netherlands, highlights the strategic move and leadership position taken up by Janssen in the oncology field, and calls on Dutch healthcare stakeholders…
Interview: Karel Fol – Country Manager Benelux, Sobi, The Netherlands
Sobi is a leading integrated biopharmaceutical company dedicated to developing innovative therapies and services to improve the lives of rare disease patients and their families. Karel Fol, the country manager…
Interview: Leo De Haan – Managing Director Benelux, Aurobindo, The…
Leo de Haan of Aurobindo discusses how to maintain a profitable business in times of rock-bottom generics prices in the Netherlands, the resulting second pillar of specialty products for the…
APAC / IFPMA's Thomas Cueni on the Value of Business Ethics for SMEs during COVID-19
Drawing on the findings of the Business Ethics for APEC SMEs Initiative, Thomas Cueni of the International Federation of Pharmaceutical Manufacturers & Associations (IFPMA) outlines the benefits for small and…
Global / Astellas CMO Bernie Zeiher: Leaving No Stone Unturned in the Quest for Patient Value
Bernie Zeiher, chief medical officer (CMO) of Astellas explains why the ‘patient-defined value’ of medicines is crucial to developing therapies that truly address patients’ unmet medical needs. Zeiher outlines some…
Vaccine Nationalism / “Moral Obscenity, Public Health Catastrophe & Economic Folly”
Over two years since the first cases of COVID-19, the world is still coming to terms with the virus. While vaccines have been developed and rolled out in record time…
Latest Report
